DHODH is an essential rate-limiting enzyme for fungal pyrimidine synthesis, controlling fungal growth and proliferation. Our DHODH inhibitors target fungal-specific DHODH active sites to block nucleotide biosynthesis and suppress fungal growth at the source.
Leveraging the structural difference between human and fungal DHODH, the drugs feature high selectivity with little impact on normal human cells, achieving outstanding efficacy and safety.
Against the backdrop of growing fungal drug resistance and the limitations of traditional injectable antifungal therapies, our innovative DHODH-targeted therapy addresses clinical unmet needs. It provides a potent, safe and convenient new treatment option for invasive fungal infections, especially for immunocompromised patients.
PCSK9 is a core protein that modulates human lipid metabolism. It induces the degradation of hepatic LDLR, weakens the clearance of blood LDL-C, and drives elevated blood lipids.
Our PCSK9 inhibitors specifically block the PCSK9-LDLR interaction, preserve hepatic LDLR expression, and efficiently promote LDL-C clearance to achieve robust lipid-lowering effects.
Hyperlipidemia has become a global chronic health burden with a younger incidence trend. Many patients cannot achieve satisfactory lipid control due to statin ineffectiveness or intolerance. Existing PCSK9 inhibitors are limited to injectable use, causing poor long-term medication compliance due to administration inconvenience and needle fear.
We are committed to developing novel oral PCSK9 therapeutics that integrate potent lipid-lowering performance, favorable safety profile and oral convenience, to address unmet clinical needs for long-term lipid management.
Cyclic peptides stand as the third major drug modality between small molecules and biological drugs. They integrate the strengths of both: excellent stability and druggability of small molecules, plus high affinity and target specificity of biologics. With stable cyclic structures, resistance to enzymatic hydrolysis and access to undruggable targets, cyclic peptides have become a high-potential track in global biopharmaceuticals.
Sungetide has built a full-chain AI-enabled R&D platform for cyclic peptide innovative drugs, covering target validation, AI molecular design, high-throughput screening, druggability optimization and clinical translation. By leveraging in-house technologies including AI simulation, mRNA display and targeted cyclic peptide modification, we efficiently discover high-activity cyclic peptide candidates while shortening R&D timelines and improving success rates.
Supported by our Shenzhen Headquarters, Shenzhen Medicinal Chemistry R&D Center and Hong Kong Clinical & Business Center, we advance original innovation, process development, global clinical development and commercialization as one integrated system. We keep delivering globally competitive First-in-Class and Best-in-Class cyclic peptide new drugs, striving to fulfill unmet clinical needs through technological innovation.
Telephone: 0755-28967200
Email: info@sungening.com
